Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention
Aroa Baragaño Raneros1, Beatriz Suarez-Álvarez2, Carlos López-Larrea3
1Department of Immunology; Hospital Universitario Central de Asturias; Oviedo, Spain.
Abstract:
Natural Killer Group 2 member D (NKG2D) activating receptor, present on the surface of various immune cells, plays an important role in activating the anticancer immune response by their interaction with stress-inducible NKG2D ligands (NKG2DL) on transformed cells. However, cancer cells have developed numerous mechanisms to evade the immune system via the downregulation of NKG2DL from the cell surface, including the release of NKG2DL from the cell surface in a soluble form. Here, we review the mechanisms involved in the production of soluble NKG2DL (sNKG2DL) and the potential therapeutic strategies aiming to block the release of these immunosuppressive ligands. Therapeutically enabling the NKG2D-NKG2DL interaction would promote immunorecognition of malignant cells, thus abrogating disease progression.
Insights
Cancer cells evade immune detection by shedding NKG2D ligands. Blocking this shedding could restore the Natural Killer Group 2 member D (NKG2D) receptor
Area of Science:
- Immunology
- Cancer Biology
- Molecular Biology
Background:
- The Natural Killer Group 2 member D (NKG2D) receptor is crucial for anti-cancer immunity.
- Cancer cells downregulate NKG2D Ligands (NKG2DL) to evade immune surveillance.
- Soluble NKG2DL (sNKG2DL) release is a key immune evasion mechanism.
Approach:
- Reviewing mechanisms of soluble NKG2DL production.
- Analyzing therapeutic strategies to inhibit NKG2DL shedding.
- Evaluating the potential of blocking sNKG2DL for cancer therapy.
Key Points:
- Cancer cells release NKG2DL as soluble factors to suppress immune responses.
- Understanding sNKG2DL production is vital for developing new cancer treatments.
- Targeting NKG2DL shedding offers a promising therapeutic avenue.
Conclusions:
- Restoring NKG2D-NKG2DL interactions can enhance anti-tumor immunity.
- Inhibiting sNKG2DL release may overcome immune evasion in cancer.
- Therapeutic strategies targeting NKG2DL shedding hold potential for disease progression abrogation.
More Related Videos
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
TGF - β Signaling Pathway
Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
The Extrinsic Apoptotic Pathway


